Trump Secures Drug Pricing Deals With Nine Pharma Companies 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
France Targets Shein, Temu With Fast-Fashion Fees 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
WINNIPEG, Manitoba, March 16, 2018 -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Thursday, March 22, 2018 at 4:30pm E.T. to discuss its financial results for the fourth quarter and full year 2017, in conjunction with the filing of its annual Year End Financial Statements for the fourth quarter and full year ended December 31, 2017.
Mark Ahrens-Townsend, President and Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.
To participate in the call, please dial +1 877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number is 2680589.
| Event: | FY+ 2017 Earnings and Business Update Conference Call | |
| Date: | Thursday, March 22, 2018 | |
| Time: | 4:30pm E.T. | |
| U.S. & Canada Dial-in: | 877-268-9044 (toll free) | |
| Conference ID: | 2680589 | |
| Webcast Link: | https://edge.media-server.com/m6/p/pvvmdwpp |
A live audio webcast of the conference call will also be available on the investor relations page of Kane’s corporate website at www.kanebiotech.com In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Kane’s website.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Mark Ahrens-Townsend
President & CEO, Kane Biotech Inc.
[email protected]
+1 (204) 477-7592
Tirth Patel
Edison Advisors
Investor Relations
[email protected]
+1 (646) 653-7035
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
